Results 11 to 20 of about 6,881 (206)
Deprescribing: An umbrella review
Acta PharmaceuticaThis umbrella review examined systematic reviews of deprescribing studies by characteristics of intervention, population, medicine, and setting. Clinical and humanistic outcomes, barriers and facilitators, and tools for deprescribing are presented.
Japelj Nuša +3 more
doaj +4 more sources
Deprescribing in migraine [PDF]
Expert Opinion on Drug Safety, 2021 The Global Burden of Diseases study (GBD2019), recently published in Lancet, reported the global disability data, expressed as years lived with disability (YLDs), of great relevance for headache di...
Paolo Martelletti +3 more
openaire +3 more sources
Deprescribing in paediatrics [PDF]
European Journal of Hospital Pharmacy, 2016 Dear Editor, Polypharmacy in paediatrics is not as common as in adults and for various reasons deprescribing is not as straightforward. There are inevitably cases whereby we have complex patients on multiple medicines, for example, complex neurological patients on drugs for dystonia, sedation, spasms, drooling and reflux.
Rukeya, Begum, Stephen, Tomlin
openaire +2 more sources
Deprescribing in older people [PDF]
British Journal of Hospital Medicine, 2020 Polypharmacy and multimorbidity are both currently rising. The number of medicines taken is the single biggest predictor of adverse drug events. Deprescribing is an approach to managing polypharmacy and reducing adverse outcomes. Multiple international evidence-based guidelines are emerging to promote discontinuation of high-risk medications, and use ...
M Sinead, O'Mahony, Anita, Parbhoo
openaire +4 more sources
Pharmacy, 2020 Pharmacists play a key role in deprescribing medications. Incorporation of this concept into pharmacy school curricula is important in ensuring that graduates can address the complex needs of an aging population.
Collin M. Clark +5 more
doaj +1 more source
Scientific Reports, 2021 No studies to investigate the effect of a deprescribing intervention on the occurrence of potential prescribing omissions (PPOs) among elderly patients with polypharmacy have been conducted.
Miho Kaminaga +2 more
doaj +1 more source
Metabolites, 2021 Medication deprescribing is essential to prevent inappropriate medication use in multimorbid patients. However, experience of deprescribing in Danish Subacute Medical Outpatient Clinics (SMOCs) is limited. The objective of our pilot study was to evaluate
Anissa Aharaz +9 more
doaj +1 more source
The role of pharmacists in deprescribing benzodiazepines: A scoping review
Exploratory Research in Clinical and Social Pharmacy, 2023 Background: Polypharmacy can increase the risk of adverse drug events, hospitalisation, and unnecessary healthcare costs. Evidence indicates that discontinuing certain medications, such as benzodiazepines, can improve health outcomes, by resolving ...
Fatemah Zakariya Ashkanani +2 more
doaj +1 more source
The attitudes and beliefs of doctors towards deprescribing medications
Proceedings of Singapore Healthcare, 2018 Background: The effects of polypharmacy and its related adverse outcomes are well documented among elderly patients. Deprescribing is now recognised as an important part of medication review in addressing polypharmacy.
Krithikaa Nadarajan +3 more
doaj +1 more source
Older people’s attitudes towards deprescribing cardiometabolic medication
BMC Geriatrics, 2021 Background Overtreatment with cardiometabolic medication in older patients can lead to major adverse events. Timely deprescribing of these medications is therefore essential. Self-reported willingness to stop medication is usually high among older people,
Stijn Crutzen +7 more
doaj +1 more source